AstraZeneca strikes $4.7bn China deal to boost weight-loss drugs pipeline
Drugmaker expands push into fast-growing market
Related reading
AstraZeneca bounces back from scandal in China
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre
US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
AstraZeneca strikes deal to lower drug costs in exchange for tariff reprieve
Chief executive Pascal Soriot applauds the deal with Donald Trump as ‘a big win’ for US patients
Pfizer closes in on $7.3bn takeover of anti-obesity drugmaker Metsera
Deal would be the biggest by a large pharma company buying a foothold in the lucrative weight-loss drug market
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history